Abstract
Alzheimer’s disease (AD), the most common form of dementia in adults, is a progressive neurodegenerative disorder of the brain characterized by loss of memory and steady deterioration of cognition. Here, a series of symmetrical molecules containing biphenyl/bibenzyl scaffolds (12–36) were designed, synthesized, and evaluated for their ability to inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). A biological evaluation showed that most of these biphenyl derivatives were potent AChE and BuChE inhibitors. Among them, compound 15 displayed the greatest ability to inhibit BuChE (IC50 = 0.74 µM) and was also a good AChE inhibitor (IC50 = 1.18 µM). Compound 19 was not only a potent AChE inhibitor (IC50 = 0.096 µM), but also a mild BuChE inhibitor (IC50 =1.25 µM). Overall, these results suggested that compound 19 may be a promising agent in the treatment of AD.
Highlights
Alzheimer’s disease (AD), the most common form of dementia in adults, is a progressive neurodegenerative disorder of the brain characterized by loss of memory and steady deterioration of cognition
Several findings indicate that amyloid-β plaques [2], tau protein aggregation [3], oxidative stress [4,5], and a low level of acetylcholine in the brain play important roles in the pathophysiology of the disease [6]
We found that compound 15 (12–36), compound showed the strongest inhibition against AChE, with an IC50 value of 0.096 μM, exhibited the strongest inhibition against BuChE, with IC50 values of 0.74 μM, which was as potent approximately the potency donepezil μM)
Summary
Alzheimer’s disease (AD), the most common form of dementia in adults, is a progressive neurodegenerative disorder of the brain characterized by loss of memory and steady deterioration of cognition. This disease currently affects more than 30 million people worldwide [1]. The exact pathophysiology of AD remains unclear. Several findings indicate that amyloid-β plaques [2], tau protein aggregation [3], oxidative stress [4,5], and a low level of acetylcholine in the brain play important roles in the pathophysiology of the disease [6]. Several research strategies have been envisaged recently, the current therapeutic option is limited to only four AChE inhibitors [7,8], namely, donepezil, rivastigmine, galantamine, and tacrine ( discontinued), and one N-methyl-D-aspartate receptor antagonist, memantine [9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
